温肺健脾化痰方辅助常规西药治疗支气管哮喘慢性持续期临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R562.2+5

基金项目:


Clinical Study on Wenfei Jianpi Huatan Prescription Assisting Routine Western Medicine for Bronchial Asthma at Chronic Duration
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察温肺健脾化痰方辅助常规西药治疗支气管哮喘慢性持续期的临床疗效。方法:选取支气管哮喘慢性持续期患者102 例,采用随机数字表法分为观察组和对照组各51 例。对照组给予常规西药治疗,观察组在对照组基础上给予温肺健脾化痰方治疗。比较2 组治疗后的临床效果,检测肺功能及协同刺激分子B7-H3、热休克蛋白70(HSP70)、嗜酸性阳离子蛋白(ECP)、白细胞介素-35(IL-35) 水平,统计中医证候积分及哮喘控制测试(ACT) 评分。结果:治疗后,2 组痰涎壅盛、喘急胸满、坐不得卧、面色青暗评分均低于治疗前,且观察组各项症状评分均低于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组第1 秒用力呼气容积(FEV1)、最大呼气流量(PEF)、呼气流速峰值(PEFR) 水平较治疗前升高,且观察组FEV1、PEF、PEFR 水平高于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组IL-35 水平较治疗前升高,B7-H3、HSP70、ECP水平较治疗前降低,且观察组各项指标均优于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组ACT 评分较治疗前升高,半年内复发次数较治疗前降低;且观察组ACT 评分高于对照组,半年内复发次数低于对照组,差异均有统计学意义(P<0.05)。结论:温肺健脾化痰方辅助常规西药治疗支气管哮喘慢性持续期可调节B7-H3、HSP70、ECP、IL-35 的表达水平,改善肺功能,减轻症状,减少复发。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Wenfei Jianpi Huatan prescription assisting routine western medicine for bronchial asthma at chronic duration. Methods:A total of 102 cases of patients with bronchial asthma at chronic duration were selected and divided into the observation group and the control group according to the random number table method,51 cases in each group. The control group was treated with routine western medicine,and the observation group was additionally treated with Wenfei Jianpi Huatan prescription based on the treatment of the control group. The clinical effect after treatment in the two groups was compared. The lung function and the levels of costimulatory molecule B7- H3,heat shock protein 70(HSP70),eosinophilic cationic protein(ECP) and interleukin-35(IL-35) were detected. The Chinese medicine syndrome scores and asthma control test(ACT) scores were counted. Results:After treatment,the scores of phlegm drool, acute panting and fullness in the chest,inability to lie flat,bluish and dark complexion in the two groups were all lower than those before treatment, and the above symptom scores in the observation group were lower than those in the control group,differences being significant(P<0.05). After treatment,the levels of forced expiratory volume in one second(FEV1), peak expiratory flow(PEF) and peak expiratory flow rate(PEFR) in the two groups were increased when compared with those before treatment, and the above levels in the observation group were higher than those in the control group, differences being significant(P<0.05). After treatment,the levels of IL-35 in the two groups were increased when compared with those before treatment, and the levels of B7- H3, HSP70 and ECP were decreased, and the indexes in the observation group were better than those in the control group,differences being significant(P<0.05). After treatment,the ACT scores in the two groups were increased when compared with those before treatment,and the recurrent numbers within half a year were decreased when compared with those before treatment; ACT score in the observation group was higher than that in the control group, and the recurrent number within half a year was fewer than that in the control group, differences being significant(P<0.05). Conclusion:Wenfei Jianpi Huatan prescription assisting routine western medicine for bronchial asthma at chronic duration can regulate the expression levels of B7-H3,HSP70,ECP and IL-35,improve the lung function,relieve symptoms and reduce recurrence.

    参考文献
    相似文献
    引证文献
引用本文

吴敏,谷彩萍,李育梅.温肺健脾化痰方辅助常规西药治疗支气管哮喘慢性持续期临床研究[J].新中医,2021,53(6):42-46

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-03-25
  • 出版日期: